245 related articles for article (PubMed ID: 34233332)
21. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
22. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
[TBL] [Abstract][Full Text] [Related]
23. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S
Haematologica; 2007 Jun; 92(6):744-52. PubMed ID: 17550846
[TBL] [Abstract][Full Text] [Related]
24. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype.
Huh YO; Tang G; Talwalkar SS; Khoury JD; Ohanian M; Bueso-Ramos CE; Abruzzo LV
Cancer Genet; 2016; 209(7-8):313-20. PubMed ID: 27318442
[TBL] [Abstract][Full Text] [Related]
25. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract][Full Text] [Related]
26. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
27. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
[TBL] [Abstract][Full Text] [Related]
28. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
29. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Daver N; Strati P; Jabbour E; Kadia T; Luthra R; Wang S; Patel K; Ravandi F; Cortes J; Qin Dong X; Kantarjian H; Garcia-Manero G
Am J Hematol; 2013 Jan; 88(1):56-9. PubMed ID: 23115106
[TBL] [Abstract][Full Text] [Related]
30. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.
Lai B; Mu Q; Zhang Y; Chen Y; Yan X; Ouyang G
Hematology; 2021 Dec; 26(1):751-757. PubMed ID: 34555298
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
[TBL] [Abstract][Full Text] [Related]
33. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
[TBL] [Abstract][Full Text] [Related]
35. Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Tremblay D; Sokol K; Bhalla S; Rampal R; Mascarenhas JO
Oncology (Williston Park); 2018 Apr; 32(4):e38-e44. PubMed ID: 29684235
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Al-Kali A; Quintás-Cardama A; Luthra R; Bueso-Ramos C; Pierce S; Kadia T; Borthakur G; Estrov Z; Jabbour E; Faderl S; Ravandi F; Cortes J; Tefferi A; Kantarjian H; Garcia-Manero G
Am J Hematol; 2013 May; 88(5):365-9. PubMed ID: 23512829
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of Coexisting Gene with NRAS in Acute Myeloid Leukemia].
Sheng YP; Hua HY; Chao HY; Zhu WY; Wang ZQ; Zhang Y; Zhou Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):351-356. PubMed ID: 35395962
[TBL] [Abstract][Full Text] [Related]
38. Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia.
Feng X; Chen X; Nie S; Chang Y; Meng F; Zhou J; Mao C; Li T; Yan X; Huang J; Liu S; Gao Y; Xiao S
J Cancer Res Ther; 2019; 15(7):1471-1476. PubMed ID: 31939424
[TBL] [Abstract][Full Text] [Related]
39. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
[TBL] [Abstract][Full Text] [Related]
40. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Braun T; Itzykson R; Renneville A; de Renzis B; Dreyfus F; Laribi K; Bouabdallah K; Vey N; Toma A; Recher C; Royer B; Joly B; Vekhoff A; Lafon I; Sanhes L; Meurice G; Oréar C; Preudhomme C; Gardin C; Ades L; Fontenay M; Fenaux P; Droin N; Solary E;
Blood; 2011 Oct; 118(14):3824-31. PubMed ID: 21828134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
